AMED - Amedisys Stock Price, News & Analysis

$56.37 1.40 (2.55 %)
(As of 11/24/2017 04:03 AM ET)
Previous Close$54.97
Today's Range$55.65 - $57.91
52-Week Range$38.00 - $65.91
Volume236,400 shs
Average Volume325,230 shs
Market Capitalization$1.91 billion
P/E Ratio26.97
Dividend YieldN/A
Beta0.68

About Amedisys (NASDAQ:AMED)

Amedisys logoAmedisys, Inc. is a healthcare services company. The Company's segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia. The Company's Home Health segment provides compassionate healthcare to help its patients recover from surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions. The Hospice segment provides support for those who are dealing with a terminal illness. The Personal care segment provides patients with assistance with the essential activities of daily living.


Industry, Sector and Symbol

Industry Home Healthcare Services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:AMED
CUSIP02343610

Debt

Debt-to-Equity Ratio0.16%
Current Ratio1.33%
Quick Ratio1.33%

Price-To-Earnings

Trailing P/E Ratio26.97
Forward P/E Ratio25.28
P/E Growth1.36

Sales & Book Value

Annual Sales$1.44 billion
Price / Sales1.33
Cash Flow$2.16 per share
Price / Cash26.07
Book Value$15.12 per share
Price / Book3.73

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS$1.25
Net Income$37.26 million
Net Margins2.88%
Return on Equity14.68%
Return on Assets9.25%

Miscellaneous

Employees16,000
Outstanding Shares33,940,000

Frequently Asked Questions for Amedisys (NASDAQ:AMED)

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

How were Amedisys' earnings last quarter?

Amedisys Inc (NASDAQ:AMED) released its earnings results on Tuesday, November, 7th. The health services provider reported $0.56 earnings per share for the quarter, topping analysts' consensus estimates of $0.54 by $0.02. The health services provider earned $380.20 million during the quarter, compared to the consensus estimate of $384.59 million. Amedisys had a return on equity of 14.68% and a net margin of 2.88%. The firm's revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.36 earnings per share. View Amedisys' Earnings History.

When will Amedisys make its next earnings announcement?

Amedisys is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Amedisys.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its third quarter earnings guidance on Tuesday, October, 24th. The company provided EPS guidance of $0.54-0.56 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.53. The company issued revenue guidance of ~$386 million, compared to the consensus revenue estimate of $385.46 million.

Where is Amedisys' stock going? Where will Amedisys' stock price be in 2017?

11 Wall Street analysts have issued 1 year price targets for Amedisys' stock. Their forecasts range from $54.00 to $70.00. On average, they anticipate Amedisys' stock price to reach $61.00 in the next year. View Analyst Ratings for Amedisys.

What are Wall Street analysts saying about Amedisys stock?

Here are some recent quotes from research analysts about Amedisys stock:

  • 1. Jefferies Group LLC analysts commented, "We are excited about AMED's 2017 outlook given our view that the company's Q4 performance (margin-driven earnings beat) foreshadows accelerating realization of benefits from its recently-completed IT rollout that should translate into strong earnings power and stock upside. Additionally, AMED's strong balance sheet and robust FCF, coupled with its $100MM EBITDA deal pipeline, should translate to an active year for accretive, upside-driving acquisitions." (3/1/2017)
  • 2. Mizuho analysts commented, "Bumps? What bumps? AMED produced 4Q16 SS home health admit growth, nice margin gains and 15% upside to our adj. EBITDA estimate. For '17E, AMED seems poised to realize $40+mm in actual cost savings, admit growth in HH and continued strong growth in hospice, enough to more than offset a $17 mm hit from HH pricing to achieve EBITDA growth of 28%+ in '17E. But the not-so-cheap stock price "knows" that even though we have no guidance yet and a brand new management team. So we reset our PT at $50 to reflect market re-rating, strong results and the prospect of the real, new AMED emerging in 2017." (3/1/2017)

Who are some of Amedisys' key competitors?

Who are Amedisys' key executives?

Amedisys' management team includes the folowing people:

  • Paul B. Kusserow, President, Chief Executive Officer, Director (Age 55)
  • Scott G. Ginn, Chief Financial Officer, Chief Accounting Officer (Age 48)
  • Christopher T. Gerard, Chief Operating Officer (Age 50)
  • Lawrence R. Pernosky, Chief Human Resource Officer (Age 63)
  • Michael Paul North, Chief Information Officer (Age 52)
  • David B. Pearce, Chief Compliance Officer (Age 56)
  • David L. Kemmerly, General Counsel (Age 54)
  • Stephen E Seim, Chief Strategy Officer (Age 53)
  • Susan Sender, Chief Clinical Operations Officer (Age 55)
  • Donald Arthur Washburn, Non-Executive Lead Independent Chairman of the Board (Age 72)

Who owns Amedisys stock?

Amedisys' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include American Century Companies Inc. (4.94%), Wells Fargo & Company MN (4.38%), Dimensional Fund Advisors LP (3.49%), Bank of New York Mellon Corp (2.50%), TimesSquare Capital Management LLC (1.83%) and Victory Capital Management Inc. (1.62%). Company insiders that own Amedisys stock include Bruce D Perkins, David B Pearce, Jake L Netterville, Lawrence R Pernosky and Scott G Ginn. View Institutional Ownership Trends for Amedisys.

Who sold Amedisys stock? Who is selling Amedisys stock?

Amedisys' stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Victory Capital Management Inc., TimesSquare Capital Management LLC, JPMorgan Chase & Co., GSA Capital Partners LLP, First Midwest Bank Trust Division, Sawgrass Asset Management LLC and Sei Investments Co.. Company insiders that have sold Amedisys company stock in the last year include David B Pearce, Jake L Netterville, Lawrence R Pernosky and Scott G Ginn. View Insider Buying and Selling for Amedisys.

Who bought Amedisys stock? Who is buying Amedisys stock?

Amedisys' stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., American Century Companies Inc., Wells Fargo & Company MN, Bank of New York Mellon Corp, Dimensional Fund Advisors LP, Tygh Capital Management Inc., Virginia Retirement Systems ET AL and Rothschild Asset Management Inc.. View Insider Buying and Selling for Amedisys.

How do I buy Amedisys stock?

Shares of Amedisys can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amedisys' stock price today?

One share of Amedisys stock can currently be purchased for approximately $56.37.

How big of a company is Amedisys?

Amedisys has a market capitalization of $1.91 billion and generates $1.44 billion in revenue each year. The health services provider earns $37.26 million in net income (profit) each year or $1.25 on an earnings per share basis. Amedisys employs 16,000 workers across the globe.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]om.


MarketBeat Community Rating for Amedisys (AMED)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  182 (Vote Outperform)
Underperform Votes:  349 (Vote Underperform)
Total Votes:  531
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Amedisys (NASDAQ:AMED)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 5 Hold Ratings, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.55)
Consensus Price Target: $61.00 (8.21% upside)

Consensus Price Target History for Amedisys (NASDAQ:AMED)

Price Target History for Amedisys (NASDAQ:AMED)

Analysts' Ratings History for Amedisys (NASDAQ:AMED)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017William BlairInitiated CoverageOutperformN/AView Rating Details
11/10/2017SunTrust Banks, Inc.Reiterated RatingBuy$70.00N/AView Rating Details
11/10/2017Robert W. BairdBoost Price TargetNeutral$50.00 -> $60.00N/AView Rating Details
11/9/2017Craig HallumReiterated RatingBuy$55.00 -> $68.00N/AView Rating Details
11/9/2017Royal Bank Of CanadaReiterated RatingSector Perform -> Sector Perform$56.00 -> $62.00N/AView Rating Details
11/9/2017Benchmark Co.Reiterated RatingBuy -> HoldN/AView Rating Details
11/8/2017MizuhoReiterated RatingBuy$55.00 -> $65.00N/AView Rating Details
10/12/2017Jefferies Group LLCReiterated RatingBuy$60.00N/AView Rating Details
9/15/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$60.00LowView Rating Details
8/21/2017Bank of America CorporationInitiated CoverageNeutral -> Neutral$55.00LowView Rating Details
5/4/2017StephensBoost Price TargetEqual Weight$50.00 -> $54.00LowView Rating Details
9/11/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
1/11/2016Raymond James Financial, Inc.UpgradeUnderperform -> Market PerformN/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Amedisys (NASDAQ:AMED)

Earnings by Quarter for Amedisys (NASDAQ:AMED)

Earnings History by Quarter for Amedisys (NASDAQ AMED)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018        
11/7/2017Q3 2017$0.54$0.56$384.59 million$380.20 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.50$0.62$380.80 million$378.80 millionViewN/AView Earnings Details
5/2/2017Q1 2017$0.41$0.47$370.03 million$370.46 millionViewListenView Earnings Details
2/28/2017Q4 2016$0.39$0.44$368.14 million$366.30 millionViewN/AView Earnings Details
11/3/2016Q3$0.36$0.36$361.08 million$361.60 millionViewListenView Earnings Details
8/2/2016Q2$0.42$0.42$353.07 million$360.00 millionViewListenView Earnings Details
5/3/2016Q1$0.33$0.33$337.07 million$348.80 millionViewListenView Earnings Details
3/8/2016Q415$0.35$0.40$322.67 million$338.37 millionViewListenView Earnings Details
11/5/2015Q315$0.34$0.34$312.22 million$326.50 millionViewListenView Earnings Details
7/29/2015Q215$0.33$0.43$307.11 million$314.20 millionViewListenView Earnings Details
4/29/2015Q115$0.20$0.30$300.17 million$301.60 millionViewListenView Earnings Details
3/4/2015Q414$0.27$0.27$301.62 million$300.50 millionViewListenView Earnings Details
10/29/2014Q314$0.17$0.28$299.26 million$300.30 millionViewListenView Earnings Details
7/30/2014Q214$0.17$0.25$298.90 million$305.00 millionViewListenView Earnings Details
5/8/2014Q114($0.06)($0.07)$301.89 million$298.74 millionViewListenView Earnings Details
3/12/2014Q413($0.01)($0.05)$295.02 million$303.50 millionViewListenView Earnings Details
11/12/2013Q313$0.13$0.06$314.30 million$301.64 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.10$0.06$328.02 million$313.10 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.18$0.13$361.41 million$339.20 millionViewListenView Earnings Details
3/12/2013Q4 2012$0.22$0.24$373.31 million$632.90 millionViewListenView Earnings Details
11/6/2012Q312$0.27$0.33$379.97 million$375.62 millionViewN/AView Earnings Details
8/7/2012$0.24$0.27ViewN/AView Earnings Details
5/8/2012$0.22$0.22ViewN/AView Earnings Details
2/28/2012$0.29$0.25ViewN/AView Earnings Details
11/1/2011$0.50$0.36ViewN/AView Earnings Details
8/2/2011$0.69$0.75ViewN/AView Earnings Details
4/26/2011$0.66$0.53ViewN/AView Earnings Details
2/22/2011$0.91$0.77ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Amedisys (NASDAQ:AMED)
2017 EPS Consensus Estimate: $2.04
2018 EPS Consensus Estimate: $2.54
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.40$0.42$0.41
Q2 20173$0.48$0.55$0.51
Q3 20173$0.53$0.55$0.54
Q4 20173$0.58$0.59$0.58
Q1 20182$0.55$0.59$0.57
Q2 20182$0.63$0.63$0.63
Q3 20182$0.64$0.67$0.66
Q4 20182$0.67$0.70$0.69
Q1 20191$0.68$0.68$0.68
Q2 20191$0.71$0.71$0.71
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Amedisys (NASDAQ:AMED)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Amedisys (NASDAQ AMED)

Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 93.94%
Insider Trades by Quarter for Amedisys (NASDAQ:AMED)
Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Insider Trades by Quarter for Amedisys (NASDAQ AMED)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/8/2017David B PearceInsiderSell1,000$50.00$50,000.00View SEC Filing  
8/3/2017Bruce D PerkinsDirectorBuy2,000$46.60$93,200.00View SEC Filing  
5/25/2017Bruce D PerkinsDirectorBuy500$59.69$29,845.00View SEC Filing  
5/12/2017Jake L NettervilleDirectorSell10,000$60.00$600,000.00View SEC Filing  
5/10/2017Lawrence R PernoskyInsiderSell11,500$58.97$678,155.00View SEC Filing  
5/9/2017Lawrence R PernoskyInsiderSell11,500$58.78$675,970.00View SEC Filing  
5/8/2017Scott G GinnInsiderSell23,828$58.62$1,396,797.36View SEC Filing  
5/13/2016Bruce D PerkinsDirectorBuy1,000$50.21$50,210.00View SEC Filing  
5/11/2016Scott G GinnInsiderSell6,000$51.62$309,720.00View SEC Filing  
11/2/2015North Tide Capital, LlcMajor ShareholderSell277,720$39.79$11,050,478.80View SEC Filing  
10/28/2015North Tide Capital, LlcMajor ShareholderSell191,400$39.86$7,629,204.00View SEC Filing  
10/26/2015North Tide Capital, LlcMajor ShareholderSell56,400$39.32$2,217,648.00View SEC Filing  
8/18/2015Donald A WashburnDirectorSell20,000$45.51$910,200.00View SEC Filing  
3/13/2015Jeffrey D JeterInsiderSell11,264$27.02$304,353.28View SEC Filing  
3/13/2015Peter RicchiutiDirectorSell2,003$27.25$54,581.75View SEC Filing  
8/5/2014Jeffrey D JeterInsiderSell2,500$21.80$54,500.00View SEC Filing  
5/8/2014North Tide Capital, Llcmajor shareholderBuy500,000$13.90$6,950,000.00View SEC Filing  
5/1/2014North Tide Capital, Llcmajor shareholderBuy150,000$13.54$2,031,000.00View SEC Filing  
11/21/2013Kkr Asset Management Llcmajor shareholderBuy425,515$14.48$6,161,457.20View SEC Filing  
11/15/2013David BuceyGeneral CounselSell8,290$13.95$115,645.50View SEC Filing  
11/14/2013Kkr Asset Management Llcmajor shareholderBuy946,500$13.89$13,146,885.00View SEC Filing  
10/30/2013Kkr Asset Management LlcMajor ShareholderBuy29,615$15.94$472,063.10View SEC Filing  
10/22/2013Kkr Asset Management LlcMajor ShareholderBuy186,013$17.55$3,264,528.15View SEC Filing  
10/18/2013Kkr Asset Management LlcMajor ShareholderBuy12,652$17.95$227,103.40View SEC Filing  
7/3/2013Linda J HallDirectorSell1,721$10.65$18,328.65View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Amedisys (NASDAQ AMED)

Source:
DateHeadline
Amedisys Inc (AMED) Coverage Initiated by Analysts at William BlairAmedisys Inc (AMED) Coverage Initiated by Analysts at William Blair
www.americanbankingnews.com - November 21 at 5:40 PM
Amedisys Inc (AMED) Receives Consensus Recommendation of "Hold" from BrokeragesAmedisys Inc (AMED) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 20 at 9:16 AM
$394.93 Million in Sales Expected for Amedisys Inc (AMED) This Quarter$394.93 Million in Sales Expected for Amedisys Inc (AMED) This Quarter
www.americanbankingnews.com - November 17 at 10:38 AM
ETFs with exposure to Amedisys, Inc. : November 14, 2017ETFs with exposure to Amedisys, Inc. : November 14, 2017
finance.yahoo.com - November 14 at 4:19 PM
Amedisys, Inc. :AMED-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017Amedisys, Inc. :AMED-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
finance.yahoo.com - November 14 at 2:43 AM
Robert W. Baird Increases Amedisys Inc (AMED) Price Target to $60.00Robert W. Baird Increases Amedisys Inc (AMED) Price Target to $60.00
www.americanbankingnews.com - November 12 at 10:30 AM
Amedisys Inc (AMED) Earns "Buy" Rating from SunTrust Banks, Inc.Amedisys Inc (AMED) Earns "Buy" Rating from SunTrust Banks, Inc.
www.americanbankingnews.com - November 11 at 4:56 PM
AMEDISYS Inc 2017 Q3 - Results - Earnings Call SlidesAMEDISYS Inc 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 11 at 9:01 AM
Stocks Showing Rising Market Leadership: Amedisys Earns 85 RS RatingStocks Showing Rising Market Leadership: Amedisys Earns 85 RS Rating
finance.yahoo.com - November 10 at 7:25 PM
Edited Transcript of AMED earnings conference call or presentation 8-Nov-17 4:00pm GMTEdited Transcript of AMED earnings conference call or presentation 8-Nov-17 4:00pm GMT
finance.yahoo.com - November 10 at 7:25 PM
2017 HomeCare Elite Recognizes Top Amedisys Care Centers Nationwide2017 HomeCare Elite Recognizes Top Amedisys Care Centers Nationwide
www.nasdaq.com - November 10 at 2:23 PM
FY2017 Earnings Estimate for Amedisys Inc (AMED) Issued By Oppenheimer HoldingsFY2017 Earnings Estimate for Amedisys Inc (AMED) Issued By Oppenheimer Holdings
www.americanbankingnews.com - November 10 at 8:34 AM
SunTrust Banks Comments on Amedisys Incs FY2017 Earnings (AMED)SunTrust Banks Comments on Amedisys Inc's FY2017 Earnings (AMED)
www.americanbankingnews.com - November 10 at 8:34 AM
Amedisys Inc (AMED) Receives "Buy" Rating from Craig HallumAmedisys Inc (AMED) Receives "Buy" Rating from Craig Hallum
www.americanbankingnews.com - November 9 at 11:55 AM
FY2017 Earnings Forecast for Amedisys Inc Issued By Jefferies Group (AMED)FY2017 Earnings Forecast for Amedisys Inc Issued By Jefferies Group (AMED)
www.americanbankingnews.com - November 9 at 8:31 AM
Amedisys (AMED) Tops Q3 EPS by 2c, Miss on RevenuesAmedisys (AMED) Tops Q3 EPS by 2c, Miss on Revenues
www.streetinsider.com - November 7 at 10:35 PM
Amedisys beats 3Q profit forecastsAmedisys beats 3Q profit forecasts
finance.yahoo.com - November 7 at 10:35 PM
Amedisys Inc (AMED) Posts Quarterly  Earnings Results, Beats Expectations By $0.02 EPSAmedisys Inc (AMED) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - November 7 at 6:54 PM
Envision Healthcare Hits 52-Week Low on Q3 Loss, Grim ViewEnvision Healthcare Hits 52-Week Low on Q3 Loss, Grim View
finance.yahoo.com - November 7 at 5:32 PM
Amedisys Reports Third Quarter 2017 Financial ResultsAmedisys Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 5:32 PM
Stocks With Rising Relative Strength: AmedisysStocks With Rising Relative Strength: Amedisys
finance.yahoo.com - November 6 at 10:00 PM
Amedisys, Inc. – Value Analysis (NASDAQ:AMED) : November 6, 2017Amedisys, Inc. – Value Analysis (NASDAQ:AMED) : November 6, 2017
finance.yahoo.com - November 6 at 10:00 PM
Amedisys, Inc.: Strong price momentum but will it sustain?Amedisys, Inc.: Strong price momentum but will it sustain?
finance.yahoo.com - November 3 at 3:52 PM
Amedisys, Inc. breached its 50 day moving average in a Bullish Manner : AMED-US : November 3, 2017Amedisys, Inc. breached its 50 day moving average in a Bullish Manner : AMED-US : November 3, 2017
finance.yahoo.com - November 3 at 9:36 AM
$385.37 Million in Sales Expected for Amedisys Inc (AMED) This Quarter$385.37 Million in Sales Expected for Amedisys Inc (AMED) This Quarter
www.americanbankingnews.com - October 27 at 6:40 AM
BRIEF-Amedisys sees Q3 net service revenues of about $380 mlnBRIEF-Amedisys sees Q3 net service revenues of about $380 mln
www.reuters.com - October 26 at 10:53 AM
Amedisys (AMED) Reports Prelim. Q3 ResultsAmedisys (AMED) Reports Prelim. Q3 Results
www.streetinsider.com - October 26 at 10:53 AM
Amedisys Inc (AMED) Given Consensus Rating of "Hold" by AnalystsAmedisys Inc (AMED) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - October 26 at 9:50 AM
Q3 2017 EPS Estimates for Amedisys Inc (AMED) Lifted by AnalystQ3 2017 EPS Estimates for Amedisys Inc (AMED) Lifted by Analyst
www.americanbankingnews.com - October 26 at 8:34 AM
Zacks: Analysts Expect Amedisys Inc (AMED) Will Post Earnings of $0.53 Per ShareZacks: Analysts Expect Amedisys Inc (AMED) Will Post Earnings of $0.53 Per Share
www.americanbankingnews.com - October 25 at 9:08 PM
Amedisys Inc (AMED) Set to Announce Quarterly Earnings on WednesdayAmedisys Inc (AMED) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 3:48 AM
Amedisys Inc (AMED) Releases Q3 Earnings GuidanceAmedisys Inc (AMED) Releases Q3 Earnings Guidance
www.americanbankingnews.com - October 24 at 9:08 PM
Amedisys Previews Strong Third Quarter 2017 ResultsAmedisys Previews Strong Third Quarter 2017 Results
finance.yahoo.com - October 24 at 5:32 PM
Amedisys Inc (AMED) Given "Hold" Rating at Royal Bank Of CanadaAmedisys Inc (AMED) Given "Hold" Rating at Royal Bank Of Canada
www.americanbankingnews.com - October 23 at 9:08 AM
Form 4 AMEDISYS INC For: Oct 18 Filed by: Ginn Scott GForm 4 AMEDISYS INC For: Oct 18 Filed by: Ginn Scott G
www.streetinsider.com - October 21 at 3:39 AM
Amedisys Inc (AMED) Given "Buy" Rating at Jefferies Group LLCAmedisys Inc (AMED) Given "Buy" Rating at Jefferies Group LLC
www.americanbankingnews.com - October 15 at 5:16 PM
Amedisys Unveils Program for Its 60,000 COPD PatientsAmedisys Unveils Program for Its 60,000 COPD Patients
www.nasdaq.com - October 12 at 4:38 PM
Jax-based health care technology company lands big clientJax-based health care technology company lands big client
finance.yahoo.com - October 11 at 5:22 PM
Amedisys Inc. (AMED) Fell To A 6-Week LowAmedisys Inc. (AMED) Fell To A 6-Week Low
www.rttnews.com - October 10 at 5:11 PM
Featured Company News - Amedisys Announces Appointment of New CFOFeatured Company News - Amedisys Announces Appointment of New CFO
finance.yahoo.com - October 10 at 5:11 PM
Amedisys, Inc. breached its 50 day moving average in a Bearish Manner : AMED-US : October 10, 2017Amedisys, Inc. breached its 50 day moving average in a Bearish Manner : AMED-US : October 10, 2017
finance.yahoo.com - October 10 at 5:11 PM
SunTrust Banks, Inc. Reiterates "Buy" Rating for Amedisys Inc (AMED)SunTrust Banks, Inc. Reiterates "Buy" Rating for Amedisys Inc (AMED)
www.americanbankingnews.com - October 9 at 3:50 PM
$388.54 Million in Sales Expected for Amedisys Inc (AMED) This Quarter$388.54 Million in Sales Expected for Amedisys Inc (AMED) This Quarter
www.americanbankingnews.com - October 8 at 3:20 AM
Amedisys promotes Ginn to chief financial officerAmedisys promotes Ginn to chief financial officer
seekingalpha.com - October 6 at 7:26 PM
Scott Ginn Promoted to Chief Financial Officer at AmedisysScott Ginn Promoted to Chief Financial Officer at Amedisys
feeds.benzinga.com - October 6 at 6:59 PM
Amedisys Arm Buys Intercity Home Care, Boosts U.S. BaseAmedisys' Arm Buys Intercity Home Care, Boosts U.S. Base
finance.yahoo.com - October 3 at 3:35 PM
Amedisys' Arm Buys Intercity Home Care, Boosts U.S. BaseAmedisys' Arm Buys Intercity Home Care, Boosts U.S. Base
finance.yahoo.com - October 3 at 3:35 PM
Amedisys Closes on Acquisition of Intercity Home CareAmedisys Closes on Acquisition of Intercity Home Care
feeds.benzinga.com - October 2 at 7:49 AM
Heres Why You Should Invest in Orthofix International NowHere's Why You Should Invest in Orthofix International Now
www.msn.com - September 27 at 8:06 PM
Bernstein Litowitz Berger & Grossmann LLP and Wolf Popper LLP Announce a Proposed Settlement of Amedisys, Inc. Securities LitigationBernstein Litowitz Berger & Grossmann LLP and Wolf Popper LLP Announce a Proposed Settlement of Amedisys, Inc. Securities Litigation
www.prnewswire.com - September 27 at 8:06 PM

Social Media

Financials

Chart

Amedisys (NASDAQ AMED) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.